The compound down-regulates BTK signaling in myeloma cells evident by reduced in vivo homing of myeloma cells to bone, prevention of myeloma-induced bone resorption, and moderate suppression of myeloma growth in primary myeloma-bearing SCID-rab mice [84]. This evidence concerns the gene BTK and plasma cell myeloma.